TMO - Thermo Fisher Scientific Inc.
216.35 +0.05 (0.02%)
After hours: 4:06PM EDT
| Previous Close | 215.89 |
| Open | 216.83 |
| Bid | 216.35 x 9200 |
| Ask | 216.36 x 400 |
| Day's Range | 215.80 - 218.05 |
| 52 Week Range | 156.03 - 226.44 |
| Volume | 1,167,639 |
| Avg. Volume | 1,462,609 |
| Market Cap | 87.042B |
| Beta | 1.34 |
| PE Ratio (TTM) | 38.69 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.68 (0.32%) |
| Ex-Dividend Date | 2018-03-14 |
| 1y Target Est | N/A |
- Zacks•7 days ago
What's in the Offing for Thermo Fisher (TMO) in Q1 Earnings?
Thermo Fisher (TMO) benefits from its acquisition of FEI, consistently adding stimulus to its analytical instruments portfolio for over a year now.
- American City Business Journals•11 days ago
Lawsuit claims Thermo Fisher discriminated against ex-Marine with PTSD
The complaint, which was filed in Boston federal court on Wednesday, alleges that Thermo Fisher violated laws barring discrimination against veterans and people with disabilities.
- Market Realist•19 days ago
Can HOLX Stock Rebound from Its Recent Lows?
Investor Update: Hologic's Recent Partnerships, Product Launches
InvestorPlace•20 days agoThe 10 Best Stocks to Buy for April
Despite its decent start, March ended up being another bad month for the market. The S&P 500 lost 2.7% of its value last month, defying the odds in doing so; the index gains an average of half a percent in the month that just ended.
Market Realist•24 days agoDiscussing BDX’s Recent Stock Price Performance
BDX's March 2018 Performance, Recommendations, and Updates
- Zacks•26 days ago
Thermo Fisher Strong on Global Business Amid Forex Woes
Thermo Fisher (TMO) witnesses solid growth globally. Foreign exchange headwinds remain.
- Zacks•last month
The Zacks Analyst Blog Highlights: Amgen, FedEx, Thermo Fisher, Sherwin-Williams and Ameriprise
The Zacks Analyst Blog Highlights: Amgen, FedEx, Thermo Fisher, Sherwin-Williams and Ameriprise
- Zacks•last month
Top Stock Reports for Amgen, FedEx & Thermo Fisher
Top Stock Reports for Amgen, FedEx & Thermo Fisher
Market Realist•last monthWhat Are Thermo Fisher Scientific’s Current Valuations?
As of March 15, 2018, Thermo Fisher Scientific (TMO) was trading at a forward PE (price-to-earnings) ratio of 19.2x. The stock has a current PE ratio of 34.9x. For the calculation of the forward PE multiple of a company, the company’s current stock price is divided by the next 12-month earnings estimates for the company. The multiple is an estimate of the potential growth of the company over the next 12 months.
- Market Realist•last month
How TMO Stock Has Performed Recently
What Analysts Recommend for Thermo Fisher Scientific
- Zacks•last month
Thermo Fisher Scientific Buys IntegenX, Widens HID Suite
Thermo Fisher Scientific (TMO) forges ahead with initiatives to strengthen its hold in the high-potential human identification market.
- The Wall Street Journal•last month
[$$] Thermo Fisher Scientific Acquires IntegenX
Thermo Fisher Scientific Inc., a Waltham, Mass.-based biotechnology product-development company, has acquired IntegenX Inc.
Market Realist•last monthWhat Investors Should Know about TMO’s Dividends
What Analysts Recommend for Thermo Fisher Scientific
- Market Realist•last month
A Look at Thermo Fisher Scientific’s Recent Research Partnerships
Thermo Fisher Scientific offers products including analytical instruments, reagents, equipment, consumables, diagnostics and research software, and services. The company has registered steady growth over recent years mainly through partnerships, collaborations, and tuck-in acquisitions. Recently, the company has entered a number of research partnerships focused on providing solutions to treat cancer and neurodegenerative diseases. On March 9, 2018, BioDiscovery and Thermo Fisher Scientific announced their partnership for the development of an end-to-end cancer research product.
- Market Realist•last month
A Look at TMO’s New High Pressure Ion Chromatography System
What Analysts Recommend for Thermo Fisher Scientific
- Reuters•last month
U.S. to cover advanced genomic testing for Medicare cancer patients
The U.S. government said on Friday it will pay for certain genetic tests for Medicare-eligible patients with advanced cancer, in a bid to help match patients with the drugs most likely to provide benefit. The Centers for Medicare & Medicaid Services (CMS) said that diagnostic laboratory tests using Next Generation Sequencing (NGS) would be covered by the government healthcare program. The National Coverage Determination (NCD) is an important step in the advance of so-called personalized medicine and follows U.S. Food and Drug Administration approvals of the tests.
- Market Realist•last month
TMO’s Advanced Laboratory Management System Could Gain Market Share
On February 27, 2018, Thermo Fisher Scientific (TMO) announced the launch of the new Thermo Scientific Chromeleon XTR Laboratory Management system, which was designed to manage an entire laboratory. The software has the ability to support data integrity, process adherence, and regulatory compliance. The system provides enhanced data software capabilities like sample management and data archiving as compared to the traditional CDS (chromatography data systems).
- Market Realist•last month
Thermo Fisher Launches New Products in Semiconductor Manufacturing
What Analysts Recommend for Thermo Fisher Scientific
- Market Realist•last month
What Analysts Recommend for Thermo Fisher Scientific
What Analysts Recommend for Thermo Fisher ScientificAnalyst recommendations
Markit•last monthSee what the IHS Markit Score report has to say about Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc NYSE:TMO
Market Realist•2 months agoA Look at Stryker’s Recent Dividend Announcement
The Latest on Stryker's Recent Developments and 2018 Expectations
- Market Realist•2 months ago
How Tax Reform Affected Medtronic’s 3Q18 Performance
The Tax Cuts and Jobs Act was enacted in the United States in December 2017, and it seems to have affected healthcare companies’ balance sheets significantly in recently reported quarters. Most medical technology companies, including Abbott Laboratories (ABT), Boston Scientific (BSX), and Thermo Fisher Scientific (TMO), reported one-time balance sheet items related to the reform.
Market Realist•2 months agoAbbott Laboratories: ABT Stock’s Wall Street Recommendations
Abbott Laboratories Updates: Dividend, Ratings, and More
Markit•2 months agoSee what the IHS Markit Score report has to say about Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc NYSE:TMO
- Market Realist•2 months ago
Boston Scientific’s 4Q17 Sales Exceeded Analysts’ Estimates
BSX Stock Recovers after a Robust 4Q17: What's to Come?
